Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Public ClinicalTrials.gov record NCT06697301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Study identification
- NCT ID
- NCT06697301
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 740 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 22, 2025 (Actual)
- Primary completion
- Dec 2035 (Estimated)
- Completion
- Dec 2040 (Estimated)
- Last update posted
- Oct 6, 2026
2025 – 2040
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | Recruiting |
| Genesis Cancer and Blood Institute | Hot Springs | Arkansas | 71913 | Recruiting |
| Helios Clinical Research | Los Angeles | California | 90015 | Recruiting |
| Providence Medical Foundation | Santa Rosa | California | 95403 | Recruiting |
| UCHealth Memorial Hospital Central | Colorado Springs | Colorado | 80909 | Recruiting |
| Christiana Care | Newark | Delaware | 19713 | Recruiting |
| Bioresearch Partner | Hialeah | Florida | 33013 | Recruiting |
| Florida Clinical Trials Group - Tamarac | Tamarac | Florida | 33321 | Recruiting |
| The Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | Recruiting |
| MidAmerica Cancer Care | Kansas City | Missouri | 64132 | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63108 | Recruiting |
| Gabrail Cancer Center Research LLC | Canton | Ohio | 44718 | Recruiting |
| University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Patientcare Clinical Research | Sugar Land | Texas | 77479 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06697301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06697301 live on ClinicalTrials.gov.